Algert Global’s Stemline Therapeutics, Inc. STML Stock Holding History

Algert Global’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-37,171	Closed	-$478K	–	429
2019 Q1	$478K	Buy	+37,171	New	+$420K	0.27%	134
2018 Q4	–	Sell	-21,458	Closed	-$356K	–	438
2018 Q3	$356K	Hold	21,458	–	–	0.08%	283
2018 Q2	$344K	Buy	+21,458	New	+$383K	0.07%	276

Other funds holding STML

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Algert Global's STML Position: Q2 2019 in Review

Algert Global sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 37,171 shares — an estimated $478K sold.

Algert Global first reported a position in STML in Q2 2018 and held it in 3 quarters. The position peaked at $478K in Q1 2019. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

Algert Global reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Algert Global sold 37,171 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $478K.
Algert Global first reported a position in Stemline Therapeutics, Inc. in Q2 2018 and held it in 3 quarters.
Algert Global's Stemline Therapeutics, Inc. position peaked at $478K in Q1 2019.
96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Algert Global's 13F filing for Q2 2019, filed 14 Aug 2019.